La Thangue, N. and Carey, N. (2006) Histone deacetylase inhibitors: gathering pace. Current Opinion in Pharmacology, 6(4), pp. 369-375. (doi: 10.1016/j.coph.2006.03.010)
Full text not currently available from Enlighten.
Abstract
Reversible histone acetylation is one of the key mechanisms involved in the epigenetic control of gene expression. A variety of recent studies has revealed a role for acetylation in a much broader repertoire of physiological processes, including proliferation control and protein folding, and has highlighted how a variety of non-histone regulatory proteins are influenced by acetylation. Inhibition of histone deacetylase (HDAC) prompts tumour cells to enter apoptosis and, as a consequence, several HDAC inhibitors have entered clinical trials. It is likely that HDAC inhibitor drugs will provide an important class of new mechanism-based therapeutics for cancer.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | UNSPECIFIED |
| Authors: | La Thangue, N., and Carey, N. |
| College/School: | College of Medical Veterinary and Life Sciences |
| Journal Name: | Current Opinion in Pharmacology |
University Staff: Request a correction | Enlighten Editors: Update this record
Altmetric
Altmetric